Annals of Clinical Microbiology and Antimicrobials

Annals of Clinical Microbiology and Antimicrobials is an open access journal from BMC, part of Springer Nature, that has published clinical microbiology, infectious disease and antimicrobial research since 2002, with a 2025 Journal Impact Factor of 5.2, a five-year impact factor of 5.6 and a median of 14 days from submission to first decision《临床微生物学与抗菌药物年鉴》（Annals of Clinical Microbiology and Antimicrobials）是（BMC，隶属施普林格·自然）出版的开放获取期刊，自 2002 年起刊载临床微生物学、感染病与抗菌药物研究，2025 年影响因子 5.2，五年影响因子 5.6，投稿至首次决定的中位时间为 14 天。

Scope

• Diagnostic and biological aspects of infectious diseases, including laboratory methods that shorten the distance between specimen and diagnosis感染病的诊断与生物学层面，包括缩短标本到诊断之间距离的实验室方法。
• Case management and treatment, from single-patient decisions to cohort-level therapeutic strategy病例管理与治疗，从单个患者的决策到队列层面的治疗策略。
• Antimicrobial development and resistance, covering new agents, susceptibility testing and the epidemiology of resistance抗菌药物的研发与耐药，涵盖新药、药敏试验与耐药流行病学。
• Work that improves communication between laboratory and clinical science, which the journal presents as its defining concern改善实验室与临床之间沟通的研究，该刊将其视为自身的核心关切。
• Reviews on important current issues are often invited, and formal systematic reviews are welcomed from unsolicited authors as well该刊常就当下重要议题约请综述，同时也欢迎作者主动投递规范的系统评价。
• Authors planning an unsolicited narrative review are asked to contact the editorial office first so that relevance and expected quality of evidence can be discussed拟投非约稿叙述性综述的作者，须先与编辑部联系，以便就选题相关性与证据质量预期进行沟通。
• The journal considers novel, international research of more than regional relevance, so single-centre descriptive audits fall outside its remit该刊只考虑具有国际意义、超出地域相关性的新颖研究，单中心描述性审计因此不在收稿范围内。

History

• The first article appeared on 16 September 2002 as article 1 of volume 1, published by BioMed Central under the 10.1186 DOI prefix that BMC still uses首篇论文于 2002 年 9 月 16 日作为第 1 卷第 1 篇文章发表，由（BioMed Central）出版，沿用（BMC）至今的 10.1186 号段（DOI）。
• It has been open access since that first volume, with no subscription edition at any point, and now publishes under a CC BY licence自首卷起即为开放获取，从未设订阅版，现以（CC BY）许可发布。
• Publication is online only and continuous, using article numbers instead of page ranges, so a citation gives the volume and the article number出版仅在线且连续进行，以文章编号代替页码，引用时给出卷号与文章编号。
• The impact factor moved from 3.944 in 2021 and 6.781 in 2022 to 3.6 in 2024 and 5.2 in 2025, when the journal ranked 42nd of 167 in microbiology影响因子由 2021 年的 3.944、2022 年的 6.781 变动至 2024 年的 3.6 与 2025 年的 5.2，该年在微生物学 167 种期刊中列第 42 位。
• In 2025 and 2026 the BMC portfolio was migrated to the Springer Nature Link platform, and the journal's old biomedcentral address now redirects there2025 至 2026 年间（BMC）刊群整体迁至（Springer Nature Link）平台，该刊原有的（BioMed Central）网址现已跳转至新站。
• Authors pay an article processing charge of 3,290 US dollars, or the euro and sterling equivalents, and the journal reports 1.1 million downloads in 2025作者需支付 3290 美元的文章处理费，另有欧元与英镑等价档，该刊 2025 年下载量达 110 万次。

Editors

• Hakan Leblebicioglu, professor of infectious diseases at VM Medical Park Hospital in Samsun, Turkey, is one of two editors-in-chief土耳其萨姆松（VM Medical Park）医院的感染病学教授（Hakan Leblebicioglu）是两位主编之一。
• Timothy D. McHugh of University College London, whose work centres on tuberculosis diagnostics and drug resistance, shares the editor-in-chief role伦敦大学学院的（Timothy D. McHugh）同为主编，研究集中于结核病诊断与耐药。
• Alfonso Rodriguez-Morales of the Fundacion Universitaria Autonoma de las Americas in Colombia serves as deputy editor-in-chief, with a portfolio in tropical and travel medicine哥伦比亚美洲自治大学基金会的（Alfonso Rodriguez-Morales）担任副主编，研究方向为热带医学与旅行医学。
• Some twenty associate editors cover bacteriology, mycology, virology and antimicrobial stewardship, among them Matthew Bates in Lincoln, Qinghua Hu at the Shenzhen CDC, Qixia Luo at Zhejiang University, Luke Moore at Imperial College and Satoshi Nishida at Teikyo University约二十位副编辑覆盖细菌学、真菌学、病毒学与抗菌药物管理，其中包括林肯大学的（Matthew Bates）、深圳市疾病预防控制中心的（Qinghua Hu）、浙江大学的（Qixia Luo）、帝国理工学院的（Luke Moore）与帝京大学的（Satoshi Nishida）。
• Peer review is single anonymous, as registered with DOAJ, and the journal reports a median of 14 days from submission to first decision据（DOAJ）登记，该刊采用单盲同行评议，官方称投稿至首次决定的中位时间为 14 天。
• The board recruits across continents, with editors based in Britain, Italy, Hungary, Ghana, India, China, Japan, Tanzania, Russia, Egypt, Spain and Colombia编委跨洲招募，编辑分布于英国、意大利、匈牙利、加纳、印度、中国、日本、坦桑尼亚、俄罗斯、埃及、西班牙与哥伦比亚。